About Us
INVESTORS

WindMIL Therapeutics is proud to have foundational financial backing from some of the life sciences industry’s most innovative and respected investors.

The company closed a $32.5 million Series B financing in the second quarter of 2018. Proceeds from that financing give WindMIL sufficient runway to achieve several significant milestones.

Domain

Foxkiser

Qiming